Anterior Cervical X-Shape-Corpectomy and Fusion Versus Anterior Cervical Corpectomy and Fusion for Cervical Spondylotic Myelopathy: A Prospective Randomized Controlled Trial.

Este estudio ha sido identificado como potencialmente de alto impacto. La métrica de alto impacto de OE, basada en la inteligencia artificial, estima la influencia que puede tener un artículo integrando señales procedentes tanto de la revista en la que se publica como del contenido científico del propio artículo. Desarrollado mediante el procesamiento del lenguaje natural más avanzado, el modelo de Alto Impacto de OE predice con mayor precisión el futuro rendimiento de las citas de un estudio que el factor de impacto de la revista por sí solo. Esto permite reconocer antes las investigaciones clínicamente significativas y ayuda a los lectores a centrarse en los artículos con más probabilidades de configurar la práctica futura.

Resumen del estudio

86 patients with one or two-level cervical spondylotic myelopathy were included and were randomized to undergo anterior cervical X-shape-corpectomy and fusion (ACXF) or anterior cervical corpectomy and fusion (ACCF). The primary outcome of interest was the composite success rate at 1 year, defined by the absence of adverse events, reoperation, or implant failure, clinically meaningful improvement in Japanese Orthopaedic Association (JOA) score and successful fusion without significant implant subsidence. Secondary outcomes included perioperative outcomes, patient-reported outcome measures (JOA, Neck Disability Index, neck and arm pain), radiological outcomes, fusion rates, and implant subsidence. Outcomes were assessed preoperatively and at 3 months, 6 months, and 1 year postoperatively. Overall, the results of the study revealed that ACXF achieved a significantly higher composite success rate, fewer medical adverse events, lower implant subsidence and improved perioperative recovery compared with ACCF, while both procedures produced comparable improvements in symptoms and cervical alignment. These findings suggest that ACXF is a safe and effective alternative to conventional ACCF for appropriately selected patients with cervical spondylotic myelopathy.